フルタミド
参考資料

↑  Schwartz, Camilla Lindgren; Christiansen, Sofie; Vinggaard, Anne Marie; Axelstad, Marta; Hass, Ulla; Svingen, Terje (2018). “Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders”. Archives of Toxicology 93 (2):  253–272. doi:10.1007/s00204-018-2350-5. ISSN 0340-5761. PMID 30430187.
↑  Kita, Diogo H.; Meyer, Katlyn B.; Venturelli, Amanda C.; Adams, Rafaella; Machado, Daria L.B.; Morais, Rosana N.; Swan, Shanna H.; Gennings, Chris et al. (2016). “Manipulation of pre and postnatal androgen environments and anogenital distance in rats”. Toxicology 368–369:  152–161. doi:10.1016/j.tox.2016.08.021. ISSN 0300-483X. PMID 27639664.
↑  William Figg; Cindy H. Chau; Eric J. Small (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. pp. 71–. ISBN 978-1-60327-829-4. https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71
↑   DICP: The Annals of Pharmacotherapy. Harvey Whitney Books Company. (1990). p. 617. https://books.google.com/books?id=N-JJAQAAIAAJ. "Additionally, 2-hydroxyflutamide has approximately a 25-fold greater affinity for androgen receptors than does flutamide."
↑  Masiello, D.; Cheng, S.; Bubley, G. J.; Lu, M. L.; Balk, S. P. (2002). “Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor”. Journal of Biological Chemistry 277 (29):  26321–26326. doi:10.1074/jbc.M203310200. ISSN 0021-9258. PMID 12015321.
1 2  Douglas T. Carrell; C. Matthew Peterson (23 March 2010). Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. Springer Science & Business Media. pp. 163–. ISBN 978-1-4419-1436-1. https://books.google.com/books?id=lcBEheiufVcC&pg=PA163
↑  “Androgens and therapeutic aspects of antiandrogens in women”. J. Soc. Gynecol. Investig. 2 (4):  577–92. (1995). doi:10.1177/107155769500200401. PMID 9420861.
1 2  J. Larry Jameson; Leslie J. De Groot (18 May 2010). Endocrinology: Adult and Pediatric. Elsevier Health Sciences. pp. 2401–. ISBN 978-1-4557-1126-0. https://books.google.com/books?id=W4dZ-URK8ZoC&pg=PA2401
↑   Hormones - Antineoplastics: Advances in Research and Application: 2011 Edition: ScholarlyPaper. ScholarlyEditions. (9 January 2012). pp. 9–. ISBN 978-1-4649-4785-8. https://books.google.com/books?id=wpCvw4TF2ZMC&pg=PA9
1 2  “The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins”. J. Steroid Biochem. 33 (2):  251–5. (August 1989). doi:10.1016/0022-4731(89)90301-4. PMID 2788775.
↑  “Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals”. Toxicology 195 (2–3):  177–86. (2004). doi:10.1016/j.tox.2003.09.012. PMID 14751673.
↑  Feau, C. (2009). Novel Small Molecule Antagonists of the Interaction of the Androgen Receptor and Transcriptional Co-regulators. Saint Jude Children's Research Hospital Memphis TN. http://www.dtic.mil/docs/citations/ADA499611
↑  Furr, B J A (1997). “Relative potencies of flutamide and 'Casodex'”. Endocrine-Related Cancer 4 (2):  197–202. doi:10.1677/erc.0.0040197. ISSN 1351-0088.
↑  “A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study”. Urology 47 (4):  497–504. (April 1996). doi:10.1016/S0090-4295(99)80484-1. hdl:2066/23543. PMID 8638357. https://hdl.handle.net/2066/23543.
↑  “Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer”. Int. J. Urol. 3 (6):  468–71. (November 1996). doi:10.1111/j.1442-2042.1996.tb00578.x. PMID 9170575.
↑  “Antiandrogen effects in models of androgen responsive cancer”. J. Steroid Biochem. 31 (4B):  711–8. (October 1988). doi:10.1016/0022-4731(88)90022-2. PMID 3059063.
↑  Ayub, M.; Levell, M.J. (1987). “Inhibition of rat testicular 17α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, ru23908, cyproterone acetate) in vitro”. Journal of Steroid Biochemistry 28 (1):  43–47. doi:10.1016/0022-4731(87)90122-1. ISSN 0022-4731. PMID 2956461.
↑  Ayub, M.; Levell, M. J. (1990). “SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE”. Clinical Endocrinology 32 (3):  329–340. doi:10.1111/j.1365-2265.1990.tb00874.x. ISSN 0300-0664. PMID 2140542.
↑  “The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4”. Biochem. Pharmacol. 119:  93–104. (November 2016). doi:10.1016/j.bcp.2016.08.021. PMC 5061623. PMID 27569425. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061623/.
↑  “Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-β1”. Oncogene 34 (50):  6092–104. (2015). doi:10.1038/onc.2015.55. PMID 25867062.
↑  Vincent DeVita; Theodore S. Lawrence; Steven A. Rosenberg (29 September 2015). Lymphomas and Leukemias: Cancer: Principles & Practice of Oncology. Wolters Kluwer Health. pp. 1029–. ISBN 978-1-4963-3828-0. https://books.google.com/books?id=n8ehCgAAQBAJ&pg=PT1029
1 2 3  “Flutamide”. 2022年3月22日閲覧。
↑   Analytical Profiles of Drug Substances and Excipients. Academic Press. (19 March 2001). pp. 155–. ISBN 978-0-08-086122-7. https://books.google.com/books?id=uEcv7SFDWBEC&pg=PA155
↑  W. Renée Acosta (1 October 2009). LWW's Foundations in Pharmacology for Pharmacy Technicians. Lippincott Williams & Wilkins. pp. 300–. ISBN 978-0-7817-6624-1. https://archive.org/details/lwwsfoundationsi0000acos
↑  Alan J. Wein; Louis R. Kavoussi; Andrew C. Novick; Alan W. Partin; Craig A. Peters (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2939–. ISBN 978-1-4160-6911-9. https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939
↑  Stabile, R. G.; Dicks, A. P. (2003). “Microscale Synthesis and Spectroscopic Analysis of Flutamide, an Antiandrogen Prostate Cancer Drug”. Journal of Chemical Education 80 (12):  1439. Bibcode: 2003JChEd..80.1439S. doi:10.1021/ed080p1439.
↑  Baker, J. W.; Bachman, G. L.; Schumacher, I.; Roman, D. P.; Tharp, A. L. (1967). “Synthesis and Bacteriostatic Activity of Some Nitrotrifluoro methylanilides”. Journal of Medicinal Chemistry 10 (1):  93–5. doi:10.1021/jm00313a020. PMID 6031711.
↑  Bandgar, B. P.; Sawant, S. S. (2006). “Novel and Gram‐Scale Green Synthesis of Flutamide”. Synthetic Communications 36 (7):  859–864. doi:10.1080/00397910500464848.
↑  DE 2130450, Neri, Rudolph O. & John G. Topliss, "Substituierte Anilide [Substituted anilides]", published 1972-12-21,  assigned to Sherico Ltd.
↑  DE 2261293, Gold, Elijah Herman, "Substituierte Imidate [Substituted imidates]", published 1973-07-05,  assigned to Sherico Ltd.
↑  H. John Smith; Hywel Williams (10 October 2005). Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth Edition. CRC Press. pp. 489–. ISBN 978-0-203-30415-0. https://books.google.com/books?id=P2W6B9FQRKsC&pg=PA489
1 2  “Synthesis and bacteriostatic activity of some nitrotrifluoromethylanilides”. J. Med. Chem. 10 (1):  93–5. (1967). doi:10.1021/jm00313a020. PMID 6031711.
↑  Barry Boettcher (12 May 2014). Immunological Influence on Human Fertility: Proceedings of the Workshop on Fertility in Human Reproduction, University of Newcastle, Australia, July 11-13, 1977. Elsevier Science. pp. 167–. ISBN 978-1-4832-6895-8. https://books.google.com/books?id=4r7iBQAAQBAJ&pg=PA167
↑   The Irish Reports: Containing Reports of Cases Argued and Determined in the Court of Appeal, the High Court of Justice, the Court of Bankruptcy, in Ireland, and the Irish Land Commission. Incorporated Council of Law Reporting for Ireland. (1990). p. 501. https://books.google.com/books?id=FQhMAQAAIAAJ
↑  William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1695–. ISBN 978-0-8155-1856-3. https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1695
↑   The Irish Reports: Containing Reports of Cases Argued and Determined in the Court of Appeal, the High Court of Justice, the Court of Bankruptcy, in Ireland, and the Irish Land Commission. Incorporated Council of Law Reporting for Ireland. (1990). pp. 501–502. https://books.google.com/books?id=FQhMAQAAIAAJ
↑  Vera Regitz-Zagrosek (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 575–. ISBN 978-3-642-30725-6. https://books.google.com/books?id=J3VxihGDh9wC&pg=PA575
↑  “Antiandrogens: clinical applications”. J. Steroid Biochem. Mol. Biol. 37 (3):  349–62. (November 1990). doi:10.1016/0960-0760(90)90484-3. PMID 2147859.
↑  “Flutamide in the treatment of hirsutism”. Int J Gynaecol Obstet 36 (2):  155–7. (1991). doi:10.1016/0020-7292(91)90772-w. PMID 1683319.
↑  “Flutamide and hirsutism”. J. Endocrinol. Invest. 17 (8):  673. (1994). doi:10.1007/BF03349685. PMID 7868809.
↑  Jean-Pierre Bégué; Daniele Bonnet-Delpon (2 June 2008). Bioorganic and Medicinal Chemistry of Fluorine. John Wiley & Sons. pp. 327–. ISBN 978-0-470-28187-1. https://books.google.com/books?id=QMVSvZ-R7I0C&pg=PA327
↑  “Endocrine changes underlying clinical effects of low-dose estrogen-antiandrogen treatment of prostatic cancer”. Endocrine Regulations 29 (1):  25–28. (1995). ISSN 0013-7200.
↑  “Koreliatsiia hormonal'nykh ta klinichnykh efektiv u khvorykh na rak peredmikhurovoï zalozy pry likuvanni niftolidom u poiednanni z malymy dozamy synestrolu [The correlation of the hormonal and clinical effects in patients with prostatic cancer undergoing niftolid treatment in combination with low doses of synestrol]” (ウクライナ語). Lik. Sprava (1–2):  107–10. (1996). ISSN 1019-5297. PMID 9005063. https://www.researchgate.net/publication/14203603.
↑  “Benefits of low dose estrogen-antiandrogen treatment of prostate cancer”. Naunyn-Schmiedebergs Archiv für Pharmakologie 358 (1):  R532. (January 1998). ISSN 0028-1298.
↑  “Mechanisms of potentiating effect of low dose estrogens on flutamide-induced suppression of normal and cancerous prostate”. Naunyn-Schmiedebergs Archiv für Pharmakologie 358 (1):  R545. (January 1998). ISSN 0028-1298.
↑  “Effects of combined treatment with niftolide and low doses of antitumor estrogen preparation, chlorotrianizene, on rat prostate”. Eksperimentalʹnai͡a onkologii͡a [Experimental Oncology] 21 (3–4):  269–273. (September 1999). ISSN 0204-3564. https://www.researchgate.net/publication/288711102.
↑  “Endocrine therapies for symptomatic benign prostatic hyperplasia”. Urology 43 (2 Suppl):  7–16. (1994). doi:10.1016/0090-4295(94)90212-7. PMID 7509536.
↑  “Flutamide in treatment of benign prostatic hypertrophy”. Urology 34 (4 Suppl):  64–8; discussion 87–96. (1989). doi:10.1016/0090-4295(89)90236-7. PMID 2477936.
1 2  “Benign prostatic hyperplasia: diagnosis and treatment guideline”. Ann Pharmacother 31 (4):  481–6. (1997). doi:10.1177/106002809703100415. PMID 9101011.
1 2  “New endocrine approaches to breast cancer”. Baillière's Clin. Endocrinol. Metab. 4 (1):  67–84. (March 1990). doi:10.1016/S0950-351X(05)80316-7. PMID 1975167.
1 2  “AR Signaling in Breast Cancer”. Cancers (Basel) 9 (3):  21. (February 2017). doi:10.3390/cancers9030021. PMC 5366816. PMID 28245550. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366816/.
↑  “A phase II clinical trial of flutamide in the treatment of advanced breast cancer”. Tumori 74 (1):  53–6. (February 1988). doi:10.1177/030089168807400109. PMID 3354065.
↑  “Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study”. Invest New Drugs 6 (3):  207–10. (September 1988). doi:10.1007/BF00175399. PMID 3192386.
↑  “Androgen Receptor as a Potential Target for Treatment of Breast Cancer”. Int J Cancer Res Mol Mech 3 (1). (April 2017). doi:10.16966/2381-3318.129. PMC 5412726. PMID 28474005. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412726/.
↑  Naessén, Sabine; Hirschberg, Angelica Lindén (2011年). “Sex Hormones and Appetite in Women: A Focus on Bulimia Nervosa”. pp. 1759–1767. doi:10.1007/978-0-387-92271-3_114
↑  “Current pharmacotherapy options for bulimia nervosa and binge eating disorder”. Expert Opin Pharmacother 13 (14):  2015–26. (2012). doi:10.1517/14656566.2012.721781. PMID 22946772.
↑  “Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide”. Acta Psychiatr Scand 94 (2):  137–9. (1996). doi:10.1111/j.1600-0447.1996.tb09838.x. PMID 8883576.
↑  “Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study”. J Clin Psychopharmacol 25 (1):  85–8. (2005). doi:10.1097/01.jcp.0000150222.31007.a9. PMID 15643104.
↑  “Anti-androgen drugs in the treatment of obsessive-compulsive disorder: a systematic review”. Curr. Med. Chem. 26 (40):  6825–6836. (December 2019). doi:10.2174/0929867326666191209142209. PMID 31814547.